Segment PerformanceGlobal Distribution and Value-Added Services sales rose 7.0% to $2.89 billion in the fourth quarter, up 5.2% on a constant-currency basis from the year-ago period.Global Specialty Products sales increased 14.6% to $422 million, or 11.1% in constant currency, driven by strong dental implant demand and solid growth in endodontics.Global Technology sales climbed 8.4% to $173 million, up 7.6% in constant currency from the fourth quarter of 2024, reflecting accelerated adoption of cloud-based ...

Key Takeaways HSIC beat Q4 earnings and revenue estimates as sales rose 7.8% year over year. HSIC saw strong growth in equipment, specialty products and cloud-based tech adoption. Margins narrowed as gross margin fell 19 bps and adjusted operating margin slipped 57 bps. Henry Schein, Inc. (HSIC) registered fourth-quarter 2025 adjusted earnings per share (EPS) of $1.34, up 12.6% from the year-ago period’s figure. The bottom line also surpassed the Zacks Consensus Estimate by 3.1%.Excluding adjustments, such ...

Henry Schein (NasdaqGS:HSIC) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsElizabeth Anderson - Senior Managing DirectorFrederick Lowery - CEO DesignateGraham Stanley - Vice President of Investor Relations and Strategic Financial Project OfficerRonald N. South - Senior Vice President and CFOStanley Bergman - Chairman of the Board and CEOConference Call ParticipantsAllen Lutz - Director and Senior Equity Research AnalystBrandon Vazquez - AnalystJason Bednar - Managing Director and S ...

Henry Schein (NasdaqGS:HSIC) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Company ParticipantsElizabeth Anderson - Senior Managing DirectorFrederick Lowery - CEO DesignateGraham Stanley - Vice President of Investor Relations and Strategic Financial Project OfficerRonald N. South - Senior Vice President and CFOStanley Bergman - Chairman of the Board and CEOConference Call ParticipantsAllen Lutz - Director and Senior Equity Research AnalystBrandon Vazquez - AnalystJason Bednar - Managing Director and S ...

Henry Schein (NasdaqGS:HSIC) Q4 2025 Earnings call February 24, 2026 08:00 AM ET Speaker11As a reminder, this call is being recorded. I would now like to introduce you to your host for today's call, Graham Stanley, Henry Schein's Vice President of Investor Relations and Strategic Financial Project Officer. Please go ahead, Graham.Speaker4Thank you, operator, and thanks to each of you for joining us today to discuss Henry Schein's financial results for the fourth quarter of 2025. With me on today's call is S ...

Q4 2025 Earnings Conference Call Financial Results & Outlook February 24, 2026 1 Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied here ...

Core Insights - Cardinal Health, Inc. reported strong second-quarter fiscal 2026 results, with adjusted earnings per share (EPS) of $2.63, exceeding estimates by 10% and showing a year-over-year increase of 36.3% [1][8] - The company raised its fiscal 2026 EPS guidance to between $10.15 and $10.35, reflecting confidence in continued strong performance across segments [10][19] Revenue Performance - Total sales increased by 18.6% year-over-year to $65.6 billion, surpassing consensus estimates by 0.9% [2] - Pharmaceutical revenues rose by 19.3% to $60.67 billion, driven by growth in branded and specialty pharmaceutical sales [3] - The Global Medical Products and Distribution segment reported revenues of $3.26 billion, up 3.3% year-over-year [4] - The Other segment, which includes at-Home Solutions and other services, saw sales of $1.72 billion, a significant increase of 34.4% year-over-year [5] Profitability Analysis - Overall gross profit increased by 23.5% year-over-year to $2.4 billion, with a gross margin of 3.7%, up almost 15 basis points [7] - The Pharmaceutical segment's profit reached $687 million, up 29.4% from the previous year, driven by brand and specialty products [4] - The Other segment's profit amounted to $179 million, reflecting a 51.7% increase year-over-year [6] Segment Outlook - The company expects Pharmaceutical segment revenues to grow by 11-13% year-over-year, with segment profit anticipated to increase by 20-22% [11] - Medical segment revenues are projected to grow by 2-4%, with profits expected to be around $150 million [11] - The Other segment is expected to see revenue growth of 26-28% and profit growth of 33-35% [12] Strategic Initiatives - The recent acquisition of Solaris is expected to enhance sales growth in the latter half of 2026, particularly in the Urology MSO space [15] - The launch of the ContinuCare Pathway program aims to improve diabetes supply management and patient access, with significant enrollment from Publix Super Markets [18] - Strong momentum in MSO platforms and anticipated growth in BioPharma Solutions sales are expected to support Specialty revenues to exceed $50 billion in fiscal 2026 [19]

Group 1 - Upslope Capital Management aims to provide attractive, equity-like returns while reducing market risk and maintaining low correlation with traditional equity strategies [1] - The Fund delivered a return of +2.0% (net) in Q4 2025, outperforming the S&P Midcap 400 ETF and HFRX Equity Hedge Index, which returned +1.6% [1] - For the full year 2025, the Fund achieved a return of +14.8%, significantly higher than the +7.2% and +10.1% returns of the respective indexes [1] Group 2 - Henry Schein, Inc. (NASDAQ:HSIC) has been added to Upslope's portfolio, with a recent stock price of $79.98 per share as of January 16, 2026 [2] - The one-month return for Henry Schein, Inc. was 3.09%, and its shares increased by 9.23% over the last 52 weeks [2] - Henry Schein, Inc. is the leading distributor of dental products in the U.S. and holds a significant market share in various countries, with 52% of Dental sales from the U.S. [3]

Core Insights - Zuckerman Investment Group has increased its stake in Henry Schein by purchasing an additional 72,040 shares, raising its total position to 281,339 shares valued at $18.67 million as of September 30 [2][3] - The purchase reflects a strategic move by the fund, which focuses on capital-efficient, cash-generating businesses, and aligns with Henry Schein's improving earnings profile and aggressive stock buybacks [10][12] Company Overview - Henry Schein, Inc. is a leading global distributor of healthcare products and services, primarily in the dental and medical markets, leveraging a vast distribution network and technology-enabled services [6][9] - The company reported a trailing twelve months (TTM) revenue of $12.94 billion and a net income of $391 million [4] Financial Performance - In the third quarter, Henry Schein's revenue increased by 5% to $3.3 billion, with adjusted EBITDA rising to $295 million and non-GAAP EPS increasing by 13% year over year to $1.38 [10] - Management has raised its full-year non-GAAP EPS guidance to a range of $4.88 to $4.96 and lifted its sales growth outlook to 3% to 4% [10] Market Position - As of the latest trading, Henry Schein's shares were priced at $76.33, reflecting an 8% increase over the past year, although this performance lags behind the S&P 500, which has risen by approximately 15.5% in the same period [3] - The company's stock buyback program included $229 million in repurchases during the quarter, with an additional $980 million authorized for future buybacks [12] Growth Initiatives - Henry Schein's global technology sales grew nearly 10%, and specialty products increased close to 6%, with management expecting over $200 million in operating income improvement from value creation initiatives in the coming years [11]

Core Insights - Cardinal Health, Inc. is a significant player in the healthcare services and products sector, with a market capitalization of $47.04 billion, focusing on the distribution of pharmaceuticals and medical supplies [1] Stock Performance - Cardinal Health's shares reached a 52-week high of $214.93 on November 26 but have since declined by 7.9% from that peak [2] - The stock has experienced a 31.2% increase over the past three months, outperforming the Nasdaq Composite index, which gained 7.8% during the same period [2] - Over the past 52 weeks, Cardinal Health's stock has gained 62.9%, and 28.9% over the past six months, while the Nasdaq Composite gained 19.5% and 20.3%, respectively [3] Financial Performance - For the first quarter of fiscal 2026, Cardinal Health reported revenues of $64.01 billion, a 22% year-over-year increase, surpassing Wall Street's expectation of $59.05 billion [4] - The company's non-GAAP EPS rose by 36% year-over-year to $2.55, exceeding the analysts' estimate of $2.21 [4] - Cardinal Health raised its fiscal 2026 non-GAAP EPS outlook from a range of $9.30-$9.50 to $9.65-$9.85, indicating projected growth of 17%-20% [5] Strategic Developments - The stock rose 15.4% intraday on October 30 following the strong quarterly results and updated outlook [5] - Cardinal Health completed the acquisition of urology MSO Solaris Health, adding over 750 providers to its multi-specialty MSO platform [5] Competitive Positioning - Compared to Cencora, Inc., which gained 40.2% over the past 52 weeks and 18.8% over the past six months, Cardinal Health has demonstrated superior performance [6]